(19)
(11) EP 1 560 821 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.05.2010 Bulletin 2010/20

(45) Mention of the grant of the patent:
24.03.2010 Bulletin 2010/12

(21) Application number: 03816120.4

(22) Date of filing: 04.11.2003
(51) International Patent Classification (IPC): 
C07D 401/06(2006.01)
 A61K 31/47(2006.01)
(86) International application number:
PCT/US2003/035201
(87) International publication number:
WO 2004/096982 (11.11.2004 Gazette 2004/46)

(54)

ANTIBACTERIAL AGENTS

ANTIBAKTERIELLE WIRKSTOFFE

AGENTS ANTIBACTERIENS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
LT LV

(30) Priority: 05.11.2002 US 423858 P

(43) Date of publication of application:
10.08.2005 Bulletin 2005/32

(73) Proprietor: Glaxo Group Limited
Greenford Middlesex UB6 0NN (GB)

(72) Inventors:
  • AXTEN, Jeffrey, Michael
    Collegeville, PA 19426 (US)
  • MILLER, William, Henry
    Collegeville, PA 19426 (US)
  • SEEFELD, Mark, Antony
    Collegeville, PA 19426 (US)

(74) Representative: Valentine, Jill Barbara et al
GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-00/21948
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).